细菌溶解产物在儿童呼吸道过敏性疾病应用的研究进展

李玉; 阚璇

doi:10.11852/zgetbjzz2021-1206

PDF(890 KB)

中国儿童保健杂志 ›› 2022, Vol. 30 ›› Issue (12) : 1336-1340. DOI: 10.11852/zgetbjzz2021-1206

综述

细菌溶解产物在儿童呼吸道过敏性疾病应用的研究进展

李玉, 阚璇

作者信息 +

Research progress in the application of bacterial lysates in children with respiratory allergic diseases

LI Yu, KAN Xuan

Author information +

文章历史 +

摘要

儿童呼吸道过敏性疾病的发生率呈逐年升高的趋势,已经成为重要的疾病负担及医疗挑战。细菌溶解产物作为一种免疫调节剂在儿童反复呼吸道感染中的应用由来已久,但在过敏性疾病中的研究还尚未深入,本文旨在综述细菌溶解产物在儿童呼吸道过敏性疾病应用的研究进展,为细菌溶解产物在儿童过敏性鼻炎(AR)及支气管哮喘的应用中提供科学依据。

Abstract

The incidence of respiratory allergic diseases in children is increasing year by year, which has become an important disease burden and medical challenge. Bacterial lysates have long been used as an immunomodulator in recurrent respiratory tract infections in children, but have not been studied in depth in allergic diseases. This paper aims to review the progress in the application of bacterial lysates in childhood respiratory allergic disease, so as to provide scientific basis for the application of bacterial lysates in the treatment of allergic rhinitis (AR) and bronchial asthma in children.

导出引用

李玉, 阚璇. 细菌溶解产物在儿童呼吸道过敏性疾病应用的研究进展[J]. 中国儿童保健杂志. 2022, 30(12): 1336-1340 https://doi.org/10.11852/zgetbjzz2021-1206

LI Yu, KAN Xuan. Research progress in the application of bacterial lysates in children with respiratory allergic diseases[J]. Chinese Journal of Child Health Care. 2022, 30(12): 1336-1340 https://doi.org/10.11852/zgetbjzz2021-1206

中图分类号： R725.6

参考文献

[1] Sly PD, Galbraith S, Islam Z, et al. Primary prevention of severe lower respiratory illnesses in at-risk infants using the immunomodulator OM-85[J]. J Allergy Clin Immunol, 2019,144(3):870-872.
[2] Marengo R, Ortega Martell JA, Esposito S. Paediatric recurrent ear, nose and throat infections and complications:Can we do more?[J]. Infect Dis Ther, 2020,9(2):275-290.
[3] Esposito S, Jones MH, Feleszko W, et al. Prevention of new respiratory episodes in children with recurrent respiratory infections: An expert consensus statement from the world association of infectious diseases and immunological disorders (WAidid)[J]. Microorganisms, 2020,8(11):1810-1810.
[4] Cantarutti A, Barbieri E, Scamarcia A, et al. Use of the bacterial lysate OM-85 in the paediatric population in Italy: A retrospective cohort study[J]. Int J Environ Res Public Health, 2021,18(13):6871.
[5] 陈莉娜, 刘瀚旻. 儿童反复呼吸道感染合理用药[J]. 中国实用儿科杂志, 2020,35(3):202-206.
[6] 中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会. 儿童反复上呼吸道感染临床诊治管理专家共识[J]. 中国实用儿科杂志, 2017,32(10):721-725.
[7] 戎萍, 马融, 张喜莲, 等. 细菌溶解产物胶囊防治儿童反复呼吸道感染有效性和安全性的Meta分析[J]. 中国药房, 2018,29(12):1702-1706.
[8] Jurkiewicz D, Zielnik-Jurkiewicz B. Bacterial lysates in the prevention of respiratory tract infections[J]. Otolaryngol Pol, 2018,72(5):1-8.
[9] Esposito S, Bianchini S, Bosis S, et al. A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections[J]. J Transl Med, 2019,17(1):284.
[10] Esposito S, Bianchini S, Polinori I, et al. Impact of OM-85 given during two consecutive years to children with a history of recurrent respiratory tract infections: A retrospective study[J]. Int J Environ Res Public Health, 2019,16(6):1065.
[11] 中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会. 儿童过敏性鼻炎诊疗—临床实践指南[J]. 中国实用儿科杂志, 2019, 34 (3):169-175.
[12] Bousquet J, Anto JM, Bachert C, et al. Allergic rhinitis[J]. Nat Rev Dis Primers, 2020,6(1):95.
[13] Blaiss MS, Hammerby E, Robinson S, et al. The burden of allergic rhinitis and allergic rhinoconjunctivitison adolescents[J]. Ann Allergy Asthma Immunol, 2018,121(1):43-52.
[14] Morjaria JB, Caruso M, Emma R, et al. Treatment of allergic rhinitis as a strategy for preventing asthma[J]. Curr Allergy Asthma Rep, 2018,18(4):23.
[15] 岳立文,曲红明,毛辰,等.南京市学龄前儿童呼吸道过敏性疾病与睡眠状况的现况研究[J]. 中国儿童保健杂志, 2016,24(12):1260-1262.
[16] Janeczek K, Emeryk A, Rachel M, et al. Polyvalent mechanical bacterial lysate administration improves the clinical course of grass pollen-induced allergic rhinitis in children: A randomized controlled trial[J]. J Allergy Clin Immunol Pract, 2021,9(1):453-462.
[17] Meng Q, Li P, Li Y,et al. Broncho-vaxom alleviates persistent allergic rhinitis in patients by improving Th1/Th2 cytokine balance of nasal mucosa.[J]. Rhinology, 2019,57(6):451-459.
[18] Banche G, Allizond V, Mandras N, et al. Improvement of clinical response in allergic rhinitis patients treated with an oral immunostimulating bacterial lysate: In vivo immunological effects[J]. Int J Immunopathol Pharmacol, 2007,20(1):129-138.
[19] Feleszko W, Rossi GA, Krenke R, et al. Immunoactive preparations and regulatory responses in the respiratory tract:Potential for clinical application in chronic inflammatory airway diseases[J]. Expert Rev Respir Med, 2020,14(6):603-619.
[20] Huang K, Yang T, Xu JY, et al. Prevalence, risk factors, and management of asthma in China: A national cross-sectional study[J]. Lancet, 2019,394(10196):407-418.
[21] 刘传合, 洪建国, 尚云晓, 等. 第三次中国城市儿童哮喘流行病学调查[J]. 中华儿科杂志, 2013,51(10):729-735.
[22] 中华儿科杂志编辑委员会, 中华医学会儿科学分会呼吸学组, 中国医师协会儿科医师分会儿童呼吸专业委员会. 儿童支气管哮喘规范化诊治建议(2020年版)[J]. 中华儿科杂志, 2020,58(09):708-717.
[23] Global Initiative for Asthma. Global strategy for asthma management and prevention, 2020[J/OL]. https://ginasthma.org/gina-reports/.
[24] Emeryk A, Bartkowiak-Emeryk M, Raus Z, et al. Mechanical bacterial lysate administration prevents exacerbation in allergic asthmatic children-The EOLIA study[J]. Pediatr Allergy Immunol, 2018,29(4):394-401.
[25] de Boer GM, Zolkiewicz J, Strzelec KP, et al. Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: A systematic review and meta-analysis[J]. Eur Respir Rev, 2020,29(158):190175.
[26] 李京阳, 包军, 鲍一笑. 细菌溶解产物OM-85BV对儿童哮喘发作及其鼻部症状的疗效研究[J]. 儿科药学杂志, 2017,23(1):7-10.
[27] Lu YM, Li YQ, Xu LY, et al. Bacterial lysate increases the percentage of natural killer T cells in peripheral blood and alleviates asthma in children[J]. Pharmacology, 2015,95(3-4):139-144.
[28] Stern J, Pier J, Litoniua AA. Asthma epidemiology and risk factors[J]. Seminars in Immunopathology, 2020,42(1):5-15.
[29] Okyere DO, Bui DS, Washko GR, et al. Predictors of lung function trajectories in population-based studies: A systematic review[J]. Respirology, 2021,26(10):938-959.
[30] Jartti T, Gern JE. Role of viral infections in the development and exacerbation of asthma in children[J]. J Allergy Clin Immunol, 2017,140(4):895-906.
[31] Bacharier LB. Azithromycin during wheezing illnesses among preschool children: Does the airway microbiota provide insights into mechanism?[J]. Am J Respir Crit Care Med, 2021,204(2):115-116.
[32] Razi CH, Harmanci K, Abaci A, et al. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children[J]. J Allergy Clin Immunol, 2010,126(4):763-769.
[33] Yin J, Xu BP, Zeng XT, et al. Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis[J]. Int Immunopharmacol, 2018,54: 198-209.
[34] Rossi GA, Pohunek P, Feleszko W, et al. Viral infections and wheezing-asthma inception in childhood: Is there a role for immunomodulation by oral bacterial lysates?[J]. Clin Transl Allergy, 2020,10(1):17.
[35] Dang AT, Pasquali C, Ludigs K, et al. OM-85 is an immunomodulator of interferon-beta production and inflammasome activity[J]. Sci Rep, 2017,7(1):43844.
[36] Ross GA, Bessler W, Ballarini S, et al. Evidence that a primary anti-viral stimulation of the immune response by OM-85 reduces susceptibility to a secondary respiratory bacterial infection in mice[J]. Ital J Pediatr, 2018,44(1):112.
[37] Roth M, Pasquali C, Stolz D, et al. Broncho Vaxom (OM-85) modulates rhinovirus docking proteins on human airway epithelial cells via Erk1/2 mitogen activated protein kinase and cAMP[J]. PLoS One, 2017,12(11):e0188010.
[38] Ferrara F, Rial A, Suarez N, et al. Polyvalent bacterial lysate protects against pneumonia independently of neutrophils, IL-17A or Caspase-1 activation[J]. Front Immunol, 2021,12:562244.
[39] Esposito S, Soto-Martinez ME, Feleszko W, et al. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: A systematic review of mechanistic and clinical evidence[J]. Curr Opin Allergy Clin Immunol, 2018,18(3):198-209.
[40] Liu YW, Dong SH, Zhan GY, et al. Analysis of the effect of bacterial lysate and the immunologic mechanism in treating infant bronchiolitis[J]. Eur Rev Med Pharmacol Sci, 2017,21(14):3332-3336.
[41] Bartkowiak-Emeryk M, Emeryk A, Rolinski J, et al. Impact of polyvalent mechanical bacterial lysate on lymphocyte number and activity in asthmatic children: A randomized controlled trial[J]. Allergy Asthma Clin Immunol, 2021,17(1):10.
[42] Liu C, Huang R, Yao RJ, et al. The immunotherapeutic role of bacterial lysates in a mouse model of asthma[J]. Lung, 2017,195(5):563-569.
[43] Han RF, Li HY, Wang JW, et al. Study on clinical effect and immunologic mechanism of infants capillary bronchitis secondary bronchial asthma treated with bacterial lysates Broncho-Vaxom[J]. Eur Rev Med Pharmacol Sci, 2016,20(10):2151-2155.